These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 16166447)

  • 61. Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.
    Zhou F; Hu J; Shao JH; Zou SB; Shen SL; Luo ZQ
    J Cancer Res Clin Oncol; 2012 Nov; 138(11):1879-90. PubMed ID: 22736027
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Theoretical investigation of the efficacy of antiangiogenic drugs combined to chemotherapy in xenografted mice.
    Lignet F; Benzekry S; Wilson S; Billy F; Saut O; Tod M; You B; Adda Berkane A; Kassour S; Wei MX; Grenier E; Ribba B
    J Theor Biol; 2013 Mar; 320():86-99. PubMed ID: 23261980
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Enhanced anti-tumor and anti-angiogenic effects of metronomic cyclophosphamide combined with Endostar in a xenograft model of human lung cancer.
    Wang R; Qin S; Chen Y; Li Y; Chen C; Wang Z; Zheng R; Wu Q
    Oncol Rep; 2012 Aug; 28(2):439-45. PubMed ID: 22641525
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
    Kerbel RS
    Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Deguelin inhibits vasculogenic function of endothelial progenitor cells in tumor progression and metastasis via suppression of focal adhesion.
    Nguyen MP; Lee D; Lee SH; Lee HE; Lee HY; Lee YM
    Oncotarget; 2015 Jun; 6(18):16588-600. PubMed ID: 26078334
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Antiangiogenic effect of low-dose cyclophosphamide combined with ginsenoside Rg3 on Lewis lung carcinoma.
    Zhang Q; Kang X; Zhao W
    Biochem Biophys Res Commun; 2006 Apr; 342(3):824-8. PubMed ID: 16499874
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells.
    Kogan NM; Blázquez C; Alvarez L; Gallily R; Schlesinger M; Guzmán M; Mechoulam R
    Mol Pharmacol; 2006 Jul; 70(1):51-9. PubMed ID: 16571653
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells.
    Dings RP; Williams BW; Song CW; Griffioen AW; Mayo KH; Griffin RJ
    Int J Cancer; 2005 Jun; 115(2):312-9. PubMed ID: 15688384
    [TBL] [Abstract][Full Text] [Related]  

  • 69. ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis.
    Anderson JC; Grammer JR; Wang W; Nabors LB; Henkin J; Stewart JE; Gladson CL
    Cancer Biol Ther; 2007 Mar; 6(3):454-62. PubMed ID: 17384534
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel.
    Ng SS; Sparreboom A; Shaked Y; Lee C; Man S; Desai N; Soon-Shiong P; Figg WD; Kerbel RS
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4331-8. PubMed ID: 16857808
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy.
    Chow A; Wong A; Francia G; Man S; Kerbel RS; Emmenegger U
    Invest New Drugs; 2014 Feb; 32(1):47-59. PubMed ID: 23728939
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy.
    Bocci G; Francia G; Man S; Lawler J; Kerbel RS
    Proc Natl Acad Sci U S A; 2003 Oct; 100(22):12917-22. PubMed ID: 14561896
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Influence of dosing schedules on toxicity and antitumour effects of combined cisplatin and docetaxel treatment in mice.
    Kodama A; To H; Kinoshita T; Ieiri I; Higuchi S
    J Pharm Pharmacol; 2009 May; 61(5):615-21. PubMed ID: 19406000
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy.
    Blansfield JA; Caragacianu D; Alexander HR; Tangrea MA; Morita SY; Lorang D; Schafer P; Muller G; Stirling D; Royal RE; Libutti SK
    Clin Cancer Res; 2008 Jan; 14(1):270-80. PubMed ID: 18172279
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Combination of low-dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities.
    Tan GH; Tian L; Wei YQ; Zhao X; Li J; Wu Y; Wen YJ; Yi T; Ding ZY; Kan B; Mao YQ; Deng HX; Li HL; Zou CH; Fu CH
    Int J Cancer; 2004 Nov; 112(4):701-6. PubMed ID: 15382054
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effects of recombinant human endostatin and its synergy with cisplatin on circulating endothelial cells and tumor vascular normalization in A549 xenograft murine model.
    Li N; Zheng D; Wei X; Jin Z; Zhang C; Li K
    J Cancer Res Clin Oncol; 2012 Jul; 138(7):1131-44. PubMed ID: 22402599
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.
    Beaudry P; Force J; Naumov GN; Wang A; Baker CH; Ryan A; Soker S; Johnson BE; Folkman J; Heymach JV
    Clin Cancer Res; 2005 May; 11(9):3514-22. PubMed ID: 15867254
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Low-dose oral metronomic chemotherapy prevents mobilization of endothelial progenitor cells into the blood of cancer patients.
    Stoelting S; Trefzer T; Kisro J; Steinke A; Wagner T; Peters SO
    In Vivo; 2008; 22(6):831-6. PubMed ID: 19181016
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Therapeutic targeting of angiogenesis with a recombinant CTT peptide-endostatin mimic-kringle 5 protein.
    Wang H; Yang Z; Gu J
    Mol Cancer Ther; 2014 Nov; 13(11):2674-87. PubMed ID: 25127900
    [TBL] [Abstract][Full Text] [Related]  

  • 80. ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer.
    Greenaway J; Henkin J; Lawler J; Moorehead R; Petrik J
    Mol Cancer Ther; 2009 Jan; 8(1):64-74. PubMed ID: 19139114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.